Hemodynamics and Vascular Regulation

Maximizing the Renal Cyclic 3′-5′-Guanosine Monophosphate System with Type V Phosphodiesterase Inhibition and Exogenous Natriuretic Peptide: A Novel Strategy to Improve Renal Function in Experimental Overt Heart Failure

Horng H. Chen, Brenda K. Huntley, John A. Schirger, Alessandro Cataliotti and John C. Burnett
JASN October 2006, 17 (10) 2742-2747; DOI: https://doi.org/10.1681/ASN.2006020161

Abstract

Type V phosphodiesterase (PDE V) metabolizes cyclic guanosine monophosphate (cGMP) and is abundant in the kidney and vasculature and was found recently in the heart. Sildenafil is a PDE V inhibitor that is used clinically for erectile dysfunction. Brain natriuretic peptide (BNP) is a cardiac peptide with vasodilating, lusitropic, and natriuretic properties that are mediated via cGMP. It was hypothesized that chronic inhibition of PDE V (PDE VI) will enhance the renal actions of exogenous BNP by potentiating the renal cGMP. The cardiorenal and humoral function was determined at baseline in two groups of dogs with pacing-induced overt chronic heart failure (CHF; 240 bpm for 10 d): Group 1 (n = 6) received Sildenafil 50 mg orally three times daily during the 10 d of pacing, and group 2 (n = 5) received no PDE V inhibitor. The response to acute subcutaneous BNP (5 μg/kg) administration also was compared in both groups on day 11. The GFR was assessed by inulin clearance (P < 0.05). There was no improvement of renal function in group 1 after 10 d of PDE VI as compared with group 2, despite having higher cardiac output (P < 0.05). Group 1 had significantly higher plasma (44 ± 2 versus 21 ± 3 pmol/ml; P < 0.05) and urinary cGMP (4219 ± 900 versus 1954 ± 300 pmol/min; P < 0.05) as compared with group 2. With acute subcutaneous BNP administration, group 1 had a natriuretic and diuretic response that was associated with an increase in GFR (30 ± 6 to 45 ± 6 ml/min; P < 0.05) and that was not observed in group 2 (25 ± 6 to 29 ± 4 ml/min). Plasma BNP increased to a similar extent in both groups with subcutaneous BNP. In contrast, group 1 had a much greater urinary cGMP excretion (4219 ± 900 to 8600 ± 1600 pmol/min; P < 0.05) as compared with group 2 (1954 ± 300 to 3580 ± 351 pmol/min; P < 0.05). In experimental overt CHF, chronic administration of PDE V inhibitor did not enhance renal function despite an improvement in cardiac output. However, chronic PDE VI significantly enhanced the renal hemodynamic and excretory responses to exogenous BNP. This study supports a role for PDE V as contributing to renal maladaptation in a model of experimental overt CHF and the strategy of maximizing the renal cGMP system by combined PDE VI and natriuretic peptides in CHF to improve renal function.

Cyclic 3′-5′-guanosine monophosphate (cGMP) is the second messenger of both the natriuretic peptide (NP) system and the nitric oxide (NO) system (1). Both of these humoral systems play important roles in the preservation of myocardial, vascular, and renal function in acute and chronic heart failure (CHF) (1–4). Recent evidence suggests that both the NP/cGMP and NO/cGMP signaling pathways are impaired in overt CHF and that such impairment may contribute to the progression of cardiorenal dysfunction in CHF (2,5). With regard to the kidney, we previously reported, as have others, that the glomerular, natriuretic, and urinary cGMP excretory responses to both atrial natriuretic peptide and brain NP (BNP) are attenuated in overt experimental and human CHF (6,7). In addition, Nesiritide, the recombinant human BNP (Scios, Inc., Fremont, CA) that is approved for the management of acute decompensated CHF, in some clinical studies failed to demonstrate a renal-enhancing property (8,9). The exact mechanisms that mediate the attenuated response to NP in overt CHF remain poorly defined and most likely are multifactorial. These mechanisms may include increased degradation of the peptides, decreased number or reduced affinity of biologic receptors or postreceptor events that lead to reduced production of cGMP, or increased cGMP degradation (2,10). Elucidation of therapeutic strategies to restore the renal responsiveness to exogenous NP would be an advance in the therapy of advanced CHF.

Type V phosphodiesterase (PDE V) metabolizes cGMP and is abundant in the kidney and vasculature and was reported recently in the heart (11,12). The exact role of PDE V in the kidney in CHF remains poorly defined, particularly in overt CHF. In contrast, in renal disease states such as nephrotic syndrome, it has been shown that PDE V contributes to renal impairment and reduced sensitivity to NP (13). Sildenafil is a PDE V inhibitor that is used clinically for erectile dysfunction and is undergoing evaluation for the management of pulmonary hypertension (14,15). Despite the importance of PDE V in the regulation of renal function, especially as a modulator of the NP and NO systems at the level of the glomerulus, the effects of chronic PDE V inhibition (PDE VI) in CHF on renal function has not been well defined. Although myocardial function has been reported to improve with chronic PDE VI in a model of experimental ventricular dysfunction (12), like other potent neurohumoral modulators, such as endothelin receptor antagonists, this may be associated with systemic vasodilation that may fail to enhance renal function in CHF despite improvements in myocardial function (16). Therefore, it remains a high priority to define the effects of chronic PDE VI on the kidney in CHF. Furthermore, the concept of maximizing the renal NP/cGMP system with PDE VI combined with exogenous BNP administration represents a novel approach in CHF that warrants further investigation.

Our study therefore was designed to address two objectives. First, we defined in a canine model of overt CHF the renal response to PDE VI with Sildenafil during 10 d of experimental CHF. This model closely mimics the renal adaptations of chronic overt CHF with impaired renal hemodynamics and avid sodium retention (16). Second, we evaluated the renal responses to exogenous BNP in the presence of chronic PDE VI in overt experimental CHF. We hypothesized that chronic PDE VI will enhance the renal actions of exogenous BNP and thus represent a novel strategy to maximize the NP/cGMP system in this syndrome of impaired cardiorenal function.

Materials and Methods

Studies were conducted in two groups of male mongrel dogs (18 to 23 kg) with overt CHF that was produced by rapid ventricular pacing at 240 bpm for 10 d on a fixed sodium diet. Group 1 (n = 6) received Sildenafil 50 mg orally three times daily (Pfizer, Inc., New York, NY) during the 10 d of pacing and one dose 1 h before the administration of canine BNP (5 μg/kg; Phoenix Pharmaceuticals, Inc., Belmont, CA) subcutaneously on day 11. Group 2 (n = 6) received no PDE V inhibitor but did receive subcutaneous canine BNP (5 μg/kg) alone on day 11 of CHF. The dosage of subcutaneous BNP used, 5 μg/kg, was based on our previous study that reported the renal actions of chronic subcutaneous BNP in experimental CHF (17). Studies were performed in accordance with the Animal Welfare Act and with approval of the Mayo Clinic Institutional Animal Care and Use Committee.

Model of Pacing-Induced Overt CHF

All dogs underwent implantation of a programmable cardiac pacemaker (Medtronic, Minneapolis, MN). Under pentobarbital sodium anesthesia (30 mg/kg intravenously) and artificial ventilation (Harvard respirator; Harvard Apparatus, Millis, MA) with 5 L/min supplemental oxygen, left lateral thoracotomy and pericardiotomy were performed. With the heart exposed, a screw-in epicardial pacemaker lead was implanted into the right ventricle. The pacemaker generator was implanted subcutaneously into the left chest wall and connected to the pacemaker lead. Dogs received pre- and postoperative prophylactic antibiotic treatment with 225 mg of clindamycin subcutaneously and 400,000 U of procaine penicillin G plus 500 mg of dihydrostreptomycin intramuscularly (Combiotic; Pfizer, Inc.). Postoperative prophylactic antibiotic was continued through the first two postoperative days. Dogs were fed a fixed sodium diet (58 mEq/d; Hill’s ID, Hill’s Pet Nutrition, Topeka, KS) and allowed water ad libitum. All dogs were walked daily. Appetite, activity, body temperature, and condition of surgical skin sites were documented. After a 14-d postoperative recovery period, the pacemaker was turned on at 240 bpm. Group 1 (n = 6) received Sildenafil 50 mg orally three times daily during the 10 d of pacing, and group 2 (n = 5) received no PDE V inhibitor.

Acute Exogenous BNP Administration

On day 11 of rapid ventricular pacing at 240 bpm, an acute experiment was performed to determine the cardiorenal and humoral function in both groups and also the response to acute subcutaneous BNP administration (5 μg/kg). On the night before experimentation, animals were fasted and given 300 mg of lithium (Li) carbonate for assessment of renal tubular function. On the morning of the experiment, only group 1 received a final dose of Sildenafil 50 mg 1 h before the dogs were anesthetized with sodium pentobarbital (15 mg/kg intravenously), intubated, and mechanically ventilated with supplemental oxygen (Harvard respirator) at 20 cycles per minute. A flow-directed balloon-tipped thermodilution catheter (Ohmeda; Criticath, Madison, WI) was advanced into the pulmonary artery via the external jugular vein for cardiac hemodynamic measurement. The femoral artery was cannulated for BP monitoring and blood sampling. The femoral vein also was cannulated for inulin and normal saline infusion. The left kidney was exposed via a flank incision, and the ureter was cannulated for urine collection. A calibrated electromagnetic flow probe was placed around the renal artery to measure renal blood flow (RBF). All of the dogs continued to be paced at 240 bpm during the acute experiment.

The experiment began after a 60-min equilibration period, with a 30-min baseline urinary clearance. After the 30-min baseline urinary clearance, subcutaneous canine BNP 5 μg/kg was administered in the right hind leg. After a 15-min lead-in period, a 60-min urinary clearance period was performed. Cardiovascular parameters that were measured during the acute experiment included mean arterial BP (MAP), right atrial pressure, mean pulmonary arterial pressure, cardiac output (CO), and pulmonary capillary wedge pressure. CO was determined by thermodilution in triplicate and averaged (Cardiac Output model 9510-A computer; American Edwards Laboratories, Irvine, CA). MAP was assessed via direct measurement from the femoral arterial catheter. Inulin was administered intravenously at the start of the equilibration period as a calculated bolus, followed by a 1-ml/min continuous infusion to achieve plasma levels of 40 to 60 mg/dl. GFR was measured by inulin clearance.

Cardiovascular hemodynamics were measured at the start of each urinary clearance. Arterial blood was collected in heparin and EDTA tubes and immediately placed on ice midway through each clearance. After centrifugation at 2500 rpm at 4°C, plasma was decanted and stored at −20°C until analysis. Urine was collected on ice during the entire period of each clearance for assessment of urine volume, electrolytes, and inulin. Urine that was collected for cGMP analysis was heated to >90°C before storage.

Hormonal and Electrolyte Analysis

Plasma samples for BNP, renin, and angiotensin II (AngII) were measured by RIA using the method as described previously (17). Plasma and urinary samples for cGMP were measured by RIA using the method of Steiner et al. (18). Urinary and plasma inulin concentrations were measured by the anthrone method (19). Urinary and plasma Li levels were determined by flame emission spectrophotometry (model 357; Instrumentation Laboratory, Wilmington, MA). Using the Li clearance (CLLi) technique, proximal tubular fractional reabsorption of sodium (PFRNa) was calculated using the equation PFRNa = [1 − (CLLi/GFR)] × 100, where CLLi = (urine Li × urine flow)/plasma Li.

Statistical Analyses

Results are expressed as mean ± SEM. Comparisons within the group were made by paired t test, and comparisons between groups were made by unpaired t test. GraphPad Prism software (GraphPad, Inc., San Diego, CA) was used for the above calculation. Statistical significance was accepted as P < 0.05.

Results

Effects of Chronic PDE VI with Sildenafil on Cardiorenal Function in Experimental CHF

Table 1 reports the cardiorenal function response to PDE VI in our model of experimental CHF with Sildenafil administered at a dosage that was based on preliminary studies and confirmed previous reports of an enhancement of cardiovascular hemodynamics. CO was higher in the PDE VI group, whereas MAP and cardiac filling pressures were similar between the two groups (Table 1). Systemic vascular resistance was lower in the PDE VI group compared with the untreated group. Despite an enhanced CO with PDE VI, urinary sodium excretion (UNaV), urine flow (UV), GFR, and RBF were not improved with Sildenafil and thus were similar between the two groups. There was a strong trend for plasma BNP to be lower in the PDE VI–treated group as compared with the untreated CHF group (Figure 1). Both plasma cGMP and urinary cGMP excretion were significantly higher in the PDE VI–treated group as compared with the untreated CHF group (Figure 1). Plasma AngII trended to be higher in the PDE VI group (165 ± 50 versus 72 ± 17 pg/ml; P = 0.1) as compared with the untreated CHF group, whereas plasma renin was similar between the two groups.

Figure 1.
Figure 1.

Plasma brain natriuretic peptide (BNP), plasma cyclic guanosine monophosphate (cGMP) and urinary cGMP excretion in the untreated congestive heart failure (CHF; □) and type V phosphodiesterase (PDE VI; ▪) groups. *P < 0.05 untreated CHF versus PDE VI.

View this table:
Table 1.

Cardiorenal and neurohumoral profilea

Cardiorenal Response to Acute Exogenous Subcutaneous BNP Administration in Experimental CHF in the Presence and Absence of Chronic PDE VI

As reported in Table 2, in both the PDE VI–treated and untreated CHF groups, pulmonary capillary wedge pressure, right atrial pressure, and pulmonary arterial pressure decreased with subcutaneous BNP administration. MAP was significantly reduced in the PDE VI–treated group, whereas it remained unchanged in the untreated CHF group. CO was unchanged in both groups with subcutaneous BNP.

View this table:
Table 2.

Hemodynamic, renal, and humoral response to exogenous subcutaneous BNPa

Figure 2 and Table 2 report GFR, UNaV, and PFRNa and other key parameters of renal function. In the PDE VI–treated group, subcutaneous BNP resulted in an increase in GFR that was not observed in the untreated CHF group. UNaV was increased and PFRNa decreased significantly with subcutaneous BNP in the PDE VI–treated group, whereas it only trended to change in the untreated CHF group. There was a trend for a greater increase in UV in the PDE VI group as compared with the untreated CHF group. RBF increased in both groups with acute BNP administration.

Figure 2.
Figure 2.

GFR, urinary sodium excretion, and proximal tubule fractional sodium reabsorption at baseline (□) and after subcutaneous BNP (▪) in the untreated CHF and PDE VI groups. *P < 0.05 PDE VI versus untreated CHF; †P < 0.05 versus baseline.

Neurohumoral Response to Acute Subcutaneous BNP in Experimental CHF in the Presence and Absence of Chronic PDE VI

Table 2 reports the neurohumoral responses in the two groups in response to acute subcutaneous BNP. With the administration of subcutaneous BNP, plasma BNP levels increased similarly in both groups. However, urinary cGMP excretion was significantly higher in the PDE VI–treated group as compared with the untreated CHF group (Table 2). Both plasma AngII and renin decreased significantly with subcutaneous BNP in the PDE VI–treated group but was unchanged in the untreated CHF group (Table 2).

Discussion

The objectives of our study were first to define the cardiorenal and humoral actions of 10 d of chronic PDE VI in a large animal model of dilated cardiomyopathy that closely mimics the cardiorenal and neurohumoral functions of human CHF with avid sodium retention, impaired GFR, and renal resistance to the NP (16). The second objective was to determine whether chronic PDE VI enhances the renal hemodynamic and tubular actions of acute exogenous BNP in experimental overt CHF. In this model of overt CHF, 10 d of PDE VI treatment did not improve renal function despite an improvement of CO but with a trend for greater activation of AngII. However, PDE VI enhanced the renal actions of acute exogenous BNP, resulting in an increase in GFR and UNaV, whereas in the untreated CHF group, exogenous BNP administration did not result in improvement of renal function. These findings provide new insights into the role of PDE V in cardiorenal regulation in CHF with important therapeutic implications.

GFR, RBF, UNaV, and UV were similar between the PDE VI–treated and untreated CHF groups. These findings were surprising in view of improved CO in the PDE VI–treated group. Previous studies demonstrated a compensatory role for the endogenous NP to maintain renal hemodynamic and excretory function in CHF (20). In the PDE VI group, however, there was a strong trend for plasma BNP to be lower as compared with the untreated CHF group. This decrease in endogenous BNP may have contributed to the lack of improvement in renal function with PDE VI. Furthermore, in the chronic PDE VI group, there was a trend for plasma AngII to be higher, possibly related to the greater systemic vasodilation with PDE VI, which also may have contributed to the lack of improvement in renal function with chronic PDE VI. It also is possible that the trend for a decrease in plasma BNP could have contributed to this trend for AngII to increase on the basis of renin and AngII inhibiting properties of the NP (21).

With the administration of exogenous BNP, there was an increase in GFR in the PDE VI group that was not observed in the untreated CHF group. Furthermore, UNaV was increased and PFRNa decreased significantly with subcutaneous BNP in the PDE VI–treated group, whereas the change was NS in the untreated CHF group. This improvement in the renal response to exogenous BNP in the PDE VI–treated group was associated with greater urinary cGMP excretion and suppression of AngII and renin.

It is well established that the renal-enhancing action of the NP is attenuated in overt CHF and is due in part to increased cGMP that is degradation by renal cGMP PDE (2). This also is true in renal disease, as Valentin et al. (13) reported in nephrotic syndrome that PDE V contributes to renal impairment and reduced sensitivity to atrial natriuretic peptide. Studies by Haneda et al. (5) and Kim et al. (3) reported that AngII and other calcium-stimulating peptides play an important role to upregulate cGMP PDE activity in both vascular smooth muscle cells and glomeruli. Our study confirms and extends previous reports and demonstrates that PDE VI potentiates the renal hemodynamic and tubular actions of exogenous BNP that were not observed in the untreated CHF group. Thus, PDE V in the kidney contributes to the maladaption of the kidneys in the syndrome of CHF with avid sodium and water retention. However, inhibition of PDE V alone does not result in improvement of renal function and may require supplemental NP therapy to realize the full renal benefits. Importantly, the exogenous BNP challenge in our study supports this conclusion while serving to test the specific pathways through which chronic PDE VI may have favorable actions, especially in the kidneys. Clearly, it seems that in the kidneys, it involves the NP system; however, the renal response was only to exogenous BNP and not to endogenous BNP. One may conclude that chronic PDE VI not alone but rather in combination with exogenous administration of BNP is an important renal-enhancing strategy that warrants further studies. Furthermore, the recent report of orally available BNP in experimental studies underscores that a strategy of combining oral PDE VI and oral BNP could emerge as a new paradigm for the treatment of cardiorenal diseases such as CHF (22).

A limitation of our study is that only one dose of sildenafil and BNP was used. However, that both plasma and urinary cGMP excretion increased with the sildenafil and also with the BNP administration supports that the dosages used for sildenafil and BNP were biologically active.

Conclusion

In this model of experimental overt CHF, chronic administration of the PDE V inhibitor Sildenafil increased both plasma and urinary cGMP but did not enhance renal function despite enhancing cardiovascular hemodynamics. Importantly, chronic PDE VI improved GFR and the natriuretic response to exogenous BNP. This study supports the therapeutic potential of a strategy to maximize the renal cGMP system by combined PDE VI and NP in CHF to improve renal function, warranting further investigations.

Acknowledgments

This research was supported by grants HL 36634, PO1 71043, and HL 07111 from the National Institutes of Health and Mayo Foundation.

We gratefully acknowledge the assistance of Denise M. Heublein, Sharon S. Sandberg, and Gail Harty.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

References

  1. ↵
    Katz SD: Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. Congest Heart Fail 9 : 9 –15, 2003
    OpenUrlPubMed
  2. ↵
    Supaporn T, Sandberg SM, Borgeson DD, Heublein DM, Luchner A, Wei CM, Dousa TP, Burnett JC Jr: Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 50 : 1718 –1725, 1996
    OpenUrlPubMed
  3. ↵
    Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC, Yan C: Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: A mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 38 : 175 –184, 2005
    OpenUrlCrossRefPubMed
  4. ↵
    Kramer HJ, Horacek V, Backer A, Vaneckova I, Heller J: Relative roles of nitric oxide, prostanoids and angiotensin II in the regulation of canine glomerular hemodynamics. A micropuncture study. Kidney Blood Press Res 27 : 10 –17, 2004
    OpenUrlCrossRefPubMed
  5. ↵
    Haneda M, Kikkawa R, Maeda S, Togawa M, Koya D, Horide N, Kajiwara N, Shigeta Y: Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int 40 : 188 –194, 1991
    OpenUrlCrossRefPubMed
  6. ↵
    Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr: Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 100 : 2443 –2448, 1999
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Margulies KB, Heublein DM, Perrella MA, Burnett JC Jr: ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol 260 : F562 –F568, 1991
  8. ↵
    Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110 : 1620 –1625, 2004
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 : 1487 –1491, 2005
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Margulies KB, Barclay PL, Burnett JC Jr: The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 91 : 2036 –2042, 1995
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass DA: Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15 : 1718 –1726, 2001
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 : 214 –222, 2005
    OpenUrlCrossRefPubMed
  13. ↵
    Valentin JP, Ying WZ, Sechi LA, Ling KT, Qiu C, Couser WG, Humphreys MH: Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann nephritis. J Am Soc Nephrol 7 : 582 –593, 1996
    OpenUrlAbstract
  14. ↵
    Lewis GD, Semigran MJ: Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr Heart Fail Rep 1 : 183 –189, 2004
    OpenUrlPubMed
  15. ↵
    Corbin JD, Beasley A, Blount MA, Francis SH: High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 334 : 930 –938, 2005
    OpenUrlCrossRefPubMed
  16. ↵
    Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC Jr: Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation 109 : 249 –254, 2004
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC Jr: Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 36 : 1706 –1712, 2000
    OpenUrlCrossRefPubMed
  18. ↵
    Steiner AL, Wehmann RE, Parker CW, Kipnis DM: Radioimmunoassay for the measurement of cyclic nucleotides. Adv Cyclic Nucleotide Res 2 : 51 –61, 1972
    OpenUrlPubMed
  19. ↵
    White RP, Samson FE Jr: Determination of inulin in plasma and urine by use of anthrone. J Lab Clin Med 43 : 475 –478, 1954
    OpenUrlPubMed
  20. ↵
    Stevens TL, Burnett JC Jr, Kinoshita M, Matsuda Y, Redfield MM: A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 95 : 1101 –1108, 1995
    OpenUrlPubMed
  21. ↵
    Burnett JC Jr, Granger JP, Opgenorth TJ: Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 247 : F863 –F866, 1984
  22. ↵
    Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, Costello-Boerrigter LC, Harty G, Heublein DM, Sandberg SM, James KD, Miller MA, Malkar NB, Polowy K, Burnett JC Jr: Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 112 : 836 –840, 2005
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Request Permissions
Maximizing the Renal Cyclic 3′-5′-Guanosine Monophosphate System with Type V Phosphodiesterase Inhibition and Exogenous Natriuretic Peptide: A Novel Strategy to Improve Renal Function in Experimental Overt Heart Failure
Horng H. Chen, Brenda K. Huntley, John A. Schirger, Alessandro Cataliotti, John C. Burnett
JASN Oct 2006, 17 (10) 2742-2747; DOI: 10.1681/ASN.2006020161
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

More in this TOC Section

Cited By...

Similar Articles

Related Articles

  • No related articles found.